Clovis Oncology ovarian cancer drug receives fast-tracked FDA approval

Clovis Oncology won the fast-tracked verdict it hoped for on Friday when the  U.S. Food and Drug Administration approved marketing the company's ovarian cancer drug rucaparib to an expanded range of patients. The FDA approved the Boulder-based company (Nasdaq: CLVS) selling rucaparib as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile. That means more women with…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news